Choose Your Country or Region

Mometasone furoate

Name: Mometasone furoate
Brand: Selleck Chemicals
SKU: S1987

Synonyms: SCH-32088,mometasone 17-furoate

Catalog No.S1987 Purity: 99.92%

Mometasone Furoate (SCH-32088,mometasone 17-furoate) is a glucocorticoid receptor agonist, used topically to reduce inflammation of the skin or in the airways.

Mometasone furoate Chemical Structure

CAS: 83919-23-7

Purity & Quality Control

Batch: Purity: 99.92%

99.92

Related compound libraries

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description

Mometasone Furoate (SCH-32088,mometasone 17-furoate) is a glucocorticoid receptor agonist, used topically to reduce inflammation of the skin or in the airways.

Targets

Glucocorticoid receptor ^[1]

In vitro
In vitro	Mometasone furoate efficiently suppresses production of cytokines including interleukin (IL)-4, IL-5, and interferon-gamma in anti-CD3-stimulated human CD4+ T cells. Mometasone furoate effectively inhibits the activation of Th cells including type 2 Th (Th2) in the draining LN, thus leading to the suppression of the IgE response. ^[1]

In Vivo
In vivo	Mometasone causes a decrease in the instances of nasal rubbing and an inhibition of this response is observed during the treatment period in rats. ^[2] Mometasone (3 mg/kg) inhibits the increased airway sensitivity to aerosolized methacholine at the highest dose tested in mice. Mometasone, given an hour after the last allergen challenge, dose-dependently inhibits the allergen-induced increase in Penh with about a 10-fold loss of potency when compared with the pre-challenge treatment schedule. ^[3] Mometasone furoate (0.02%) and fluticasone propionate (0.1%) significantly inhibits the increase of antigen-induced nasal rubbing even 6 hours after topical application, indicating that both drugs have a long-lasting effect. ^[4] Mometasone furoate dose-dependently inhibits the elevated eosinophil numbers in the bronchoalveolar lavage fluid and lung tissues of sensitized, ovalbumin challenged mice. Mometasone furoate (33 mg/kg) reduces the percentage of CD44+ T-helper cells (activated/memory cells) to the levels observed in non-sensitized, ovalbumin-challenged mice. ^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT02967731	Completed	Chronic Sinusitis	Lyra Therapeutics	June 6 2017	Phase 1
NCT01894503	Completed	Chronic Sinusitis	Intersect ENT	June 2013	Phase 2
NCT01702103	Unknown status	Nasal Obstruction\|Sneezing\|Itching	PH&T S.p.A.	October 2012	Phase 3

References

+ Expand

Chemical lnformation & Solubility

Molecular Weight	521.43	Formula	C₂₇H₃₀C_l2O₆
CAS No.	83919-23-7	SDF	Download Mometasone furoate SDF
Smiles	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 25 mg/mL ( (47.94 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):